Emicizumab Clinical Trials
9 recruitingDrug
Phase 33Phase 43Phase 11
Showing 1–9 of 9 trials
Recruiting
Phase 3
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
Hemophilia A
Emory University5 enrolled2 locationsNCT04563520
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
Von Willebrand Disease, Type 3
Hoffmann-La Roche75 enrolled27 locationsNCT06998524
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Hemophilia A
Hoffmann-La Roche360 enrolled3 locationsNCT07416604
Recruiting
Phase 1
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Von Willebrand Disease, Type 3Concomitant VWD and Hemophilia
Bleeding and Clotting Disorders Institute Peoria, Illinois40 enrolled12 locationsNCT05500807
Recruiting
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
Hemophilia A
Wayne State University72 enrolled9 locationsNCT05022459
Recruiting
Phase 4
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
Hemophilia A
Sanofi20 enrolled2 locationsNCT06145373
Recruiting
Treatment of Hemophilia A Patients With FVIII Inhibitors
Hemophilia A
Emory University120 enrolled2 locationsNCT04023019
Recruiting
Phase 4
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
Hemophilia AFactor VIII
University of Texas Southwestern Medical Center28 enrolled1 locationNCT04690322
Recruiting
Phase 4
Hemlibra in Mild Hemophilia A
Factor VIII Deficiency, Congenital
Indiana Hemophilia &Thrombosis Center, Inc.20 enrolled1 locationNCT04567511